UCB agreed to buy Neurona for up to $1.2 billion, aiming to add a potentially one-off seizure cell therapy to its primarily small-molecule portfolio. The transaction is intended to diversify UCB’s approach to seizure treatment and expand exposure to an early-stage therapy in a hard-to-treat form of common epilepsy. For investors and pipeline planners, the deal signals continued corporate interest in cell therapies that may complement or outperform chronic pharmacology in defined patient populations.